1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alvotech Starts European Trial For High-Concentration Adalimumab

 
• By Aidan Fry

Icelandic developer Alvotech is looking to set itself apart from the pack offering biosimilar rivals to Humira by conducting a Phase III clinical trial for an alternative to AbbVie’s high-concentration 100mg/ml version of adalimumab, the world’s best-selling drug.

HeadStatue
Alvotech is studying in plaque psoriasis patients its biosimilar of AbbVie's high-concentration version of Humira • Source: Shutterstock

Alvotech says it has enrolled the first patient in a clinical Phase III study for a biosimilar version of AbbVie’s 100mg/ml high-concentration version of Humira (adalimumab). By offering its AVT02 formulation that has a reduced injection volume, and is thus more convenient for patients, the Icelandic developer believes it will be “well positioned to differentiate from biosimilars competitors”.

Adalimumab 100mg/ml is the Icelandic firm’s lead biosimilar candidate in a pipeline of seven monoclonal antibodies that also includes aflibercept,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

More from Products